Innovative biotechnologies: bacteriophages against infections
Pherecydes Pharma raises €8.7M ($10.3M)
Romainville, France, January 16, 2018 - Series B financing led by GO CAPITAL and two historical investors, ACE Management and Auriga Partners Funds will allow company to produce phages according to Good Manufacturing Practices (GMP), initiate clinical trials with two new products and set up a pharmaceutical production unit in Nantes.
Bacteriophages: natural viruses of bacteria
They are harmless to eukaryote organisms (humans, animals, fishes, plants, insects, algae’s, etc).
When they recognize their bacterial target, they attach to its outer membrane, inject their genetic material and reproduce in their host to make new phages that get out and repeat the same cycle.
The lytic phages, those we are interested in, kill properly the bacteria as their progeny leave their host.
a growing threat
Over the years, bacteria succeeded to develop mechanisms to evade antibiotics.
This antibiotic resistance is not new, but the phenomenon has increased dramatically during the past 10 to 15 years.
The increasing threat of resistance to existing antibiotics has been the major driver of the renewed interest in bacteriophage treatment.
In less than 10 years, Pherecydes Pharma has established itself as the champion of phage therapy. Following the development of the first pharmaceutical manufacturing process for bacteriophage, Pherecydes Pharma is the first company to have obtained authorizations for conducting a clinical trial to directly test its phages on hospitalized patients.
Jérôme Gabard, Chief Operating Officer at Pherecydes Pharma
Antibiotic resistance is a major health challenge in the years to come: 10 million people may die in 2050. New approaches are needed; Phage therapy represents the most promising hope. Pherecydes Pharma makes every effort to provide physicians and patients with effective treatments for the most serious bacterial infections.
Guy-Charles Fanneau de La Horie, Chief Executive Officer at Pherecydes Pharma